

Physician & Payer Forum

Primary Market Research at a
Multiclient Price



2009 Titles



Will Prescribers and Payers Allow Branded AEDs to Stem the Tide of Generics in Epilepsy, Migraine, Neuropathic Pain or Bipolar Disorder?

The JUPITER trial: Will Physicians and Payers Support a Change in Statin Prescribing?

TNF-alpha Inhibitors in Pediatric Crohn's Disease and Juvenile RA: How Will Physicians and Payers Balance Effective Treatments and Serious Safety Concerns?

Novel Anticoagulants for Venous Thromboembolism and Stroke Prevention in Atrial Fibrillation: Will Prescribers' and Payers' Attitudes Promote or Prevent a Shift Away from Warfarin and Heparins?

Vytorin One Year On: How Will Prescriber Attitudes and Payer Hurdles Influence the Markets for Dyslipidemia?

A Clinician and Payer Perspective on Changing Dynamics in the Diabetes Market: Is There Room for New GLP-1 Analogues or DPP-IV Inhibitors?

Hepatitis C: Impact of Novel Antivirals and Receptivity Among Payors

Multiple Sclerosis: How Will Clinician Attitudes and Reimbursement Issues Determine How Oral Agents Will Compete with Current Disease Modifying Drugs in this Dynamic Landscape?

Is Avastin Unassailable? Will Its Dominance in Breast, Colorectal and Lung Cancer be Challenged by Drugs with Validated Biomarkers?

The Rheumatoid Arthritis Biologics Landscape: Differentiation and Reimbursement in a Crowded Market

The Next Wave of Psoriasis Biologics: Physician and Payer Perspectives on Ustekinumab



A Decision Resources, Inc. Company

www.DecisionResources.com